SHEP-Pilot Study, a randomized, double-blind, placebo-controlled trial of drug therapy for isolated systolic hypertension, followed 551 participants aged 60 years or more with untreated blood pressures of greater than or equal to 160/less than 90 mmHg for an average of 34 months. Mean age was 72 years, 63% were female and 82% white. Pretreatment blood pressures averaged 172/75 mmHg. As their Step I drug, 443 participants were assigned chlorthalidone and 108 placebo. Of 512 surviving participants, 80% and 84% of the chlorthalidone and placebo groups, respectively, attended their last clinic visit; 71% and 60% were still taking blinded drug; and 60% and 33% had systolic blood pressures less than 160 mmHg. Final blood pressures averaged 140/67 and 154/72 mmHg for the chlorthalidone and placebo groups, respectively. All-cause mortality rates were 25 and 23 deaths per 1000 participant-years of risk, respectively; rates for 'definite' first strokes were 8.3 and 13 deaths. Differences between chlorthalidone and placebo groups were significant for blood pressure but not for event rates.

Chlorthalidone

Systolic hypertension

Placebo group

Antihypertensive drug

Source

Cite

Citations (24)

Evaualtion of the performance of ambulatory care systems: research requirements and opportunities.

PubMed (1973)

Freeborn Dk Greenlick Mr

Source

Cite

Citations (17)

The emergence of population-based medicine.

PubMed (1995)

Greenlick Mr

Source

Cite

Citations (11)

New health professionals and the physician role: An hypothesis from Kaiser experience.

PubMed (1975)

Record Jc Greenlick Mr

Health Professionals

Source

Cite

Citations (9)

The Clinton administration's proposed Health Security Act.

PubMed (1994)

Greenlick Mr

Source

Cite

Citations (0)

Developing a future for the dental group in a neighborhood health center--implications for the present.

PubMed (1970)

Creighton We Colombo Tj Saward Ew Greenlick Mr

Center (category theory)

Source

Cite

Citations (1)

The HMO as a health promotion laboratory.

PubMed (1989)

Stevens Vj Greenlick Mr

HMOs offer unparalleled opportunities as a setting for health promotion research while providing the health care system with direct and immediate benefits. The special advantages of doing health promotion research in an HMO include easy access to a large, relatively stable population; access to all aspects of the health care system; access to a unified, comprehensive medical record; and working within an organization that views health promotion activities as an essential part of its mission. This article reviews these advantages and illustrates how they have been used in a diverse series of research and demonstration projects conducted within the Northwest Region of Kaiser Permanente.

Promotion (chess)

Population Health

Source

Cite

Citations (0)